Geron Corp (GERN) — SEC Filings
Geron Corp (GERN) — 35 SEC filings. Latest: DEFA14A (Apr 7, 2026). Includes 15 8-K, 6 10-Q, 6 SC 13G/A.
Overview
Geron Corp (GERN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 7, 2026: Geron Corporation filed a Definitive Additional Materials (DEFA14A) on April 7, 2026. This filing contains additional proxy soliciting materials related to the company's business. The filing includes graphic documents, suggesting visual aids were used in the solicitation process.
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 32 neutral, 1 mixed. The dominant filing sentiment for Geron Corp is neutral.
Filing Type Overview
Geron Corp (GERN) has filed 1 DEFA14A, 15 8-K, 6 10-Q, 2 DEF 14A, 1 8-K/A, 2 10-K, 6 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of GERN's 22 recent filings, 1 were flagged as high-risk, 8 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $135.866M |
| Net Income | $(54.638M) |
| EPS | $(0.08) |
| Debt-to-Equity | N/A |
| Cash Position | $78.117M |
| Operating Margin | N/A |
| Total Assets | $567.382M |
| Total Debt | $119.264M |
Key Executives
- Andrew J. Grethlein, PhD
- December 29, 2023
Industry Context
The biotechnology sector, particularly in oncology, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Geron operates in the hematology/oncology space, facing competition from established pharmaceutical companies and emerging biotechs. Success hinges on clinical efficacy, regulatory approval, and effective commercialization of novel therapies like RYTELO.
Top Tags
corporate-governance (5) · 10-Q (5) · financials (4) · filing (4) · pharmaceuticals (4) · sec-filing (3) · SEC Filing (3) · amendment (3) · Geron Corp (3) · institutional-ownership (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product Revenue, Net (Q3 2025) | $47.167M | Increased from $28.209M in Q3 2024, a 67.2% increase, driven by RYTELO sales. |
| Product Revenue, Net (9M 2025) | $135.610M | Significantly up from $28.989M in 9M 2024, a 367.8% increase, indicating strong RYTELO market penetration. |
| Net Loss (Q3 2025) | $(18.428M) | Improved from $(26.447M) in Q3 2024, a 30.3% reduction in loss. |
| Net Loss (9M 2025) | $(54.638M) | Substantially improved from $(149.220M) in 9M 2024, a 63.3% reduction in loss. |
| Interest Expense (Q3 2025) | $8.644M | Increased from $3.046M in Q3 2024, a 183.8% rise, reflecting higher debt burden. |
| Interest Expense (9M 2025) | $25.360M | Increased from $9.798M in 9M 2024, a 158.8% rise. |
| Inventory (Sept 30, 2025) | $95.422M | Increased from $38.714M at Dec 31, 2024, a 146.5% increase, indicating scaled RYTELO production. |
| Cash and Cash Equivalents (Sept 30, 2025) | $78.117M | Slightly down from $79.016M at Dec 31, 2024, indicating cash burn despite revenue growth. |
| Common Stock Shares Outstanding (Nov 4, 2025) | 638,355,275 | Increased from 606,387,666 at Dec 31, 2024, indicating dilution from equity issuances. |
| Product Revenue | $0 | No product revenue for Q2 2025 or YTD 2025, indicating no commercialized products. |
| Royalty Revenue | $0 | No royalty revenue for Q2 2025 or YTD 2025, indicating no licensing income. |
| Retained Earnings Deficit | -$1.43B | Increased from -$1.36 billion at Dec 31, 2024, to -$1.43 billion at June 30, 2025, reflecting ongoing losses. |
| Capital Raised | $100.0M | From public offering of common stock and warrants in Q1 2024, demonstrating reliance on equity financing. |
| Additional Paid-In Capital | $1.8B | As of June 30, 2025, reflecting significant capital raised through equity issuances. |
| Reporting Period End Date | 2025-03-31 | Quarterly financial reporting |
Forward-Looking Statements
- {"claim":"Geron Corp's stock price will experience increased stability due to Vanguard's significant passive stake.","entity":"Geron Corp","targetDate":"Next 6-12 months","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Geron Corp (GERN)?
Geron Corp has 35 recent SEC filings from Jan 2024 to Apr 2026, including 15 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GERN filings?
Across 35 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 32 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Geron Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Geron Corp (GERN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Geron Corp?
Key financial highlights from Geron Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GERN?
The investment thesis for GERN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Geron Corp?
Key executives identified across Geron Corp's filings include Andrew J. Grethlein, PhD, December 29, 2023.
What are the main risk factors for Geron Corp stock?
Of GERN's 22 assessed filings, 1 were flagged high-risk, 8 medium-risk, and 13 low-risk.
What are recent predictions and forward guidance from Geron Corp?
Recent forward-looking statements from Geron Corp include guidance on {"claim":"Geron Corp's stock price will experience increased stability due to Vanguard's significant passive stake.","en.